ARTERIAL HYPERTENSION DURING THERAPY OF ONCOLOGICAL DISEASES WITH ANGIOGENESIS INHIBITORS: SERIOUS IMPEDIMENT OR CONTROLLED REACTION?
Vascular endothelial growth factor signaling pathway (VSP) inhibitors are drugs for which arterial hypertension (AH) is a class effect, occurring with a frequency of up to 73 % of treated patients. Blockade of vascular endothelial growth factor or its receptor is accompanied by inhibition of the syn...
Saved in:
| Main Authors: | Zh. D. Kobalava, E. K. Shavarova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2017-06-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/268 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
VASCULAR REMODELING IN HYPERTENSION: ANGIOGENESIS FEATURES
by: L. A. Haisheva, et al.
Published: (2014-07-01) -
Vascular endothelial growth factor inhibitors in the treatment of ovarian cancer
by: S. V. Khokhlova
Published: (2014-08-01) -
Changes in angiogenesis markers during neoadjuvant treatment for locally advanced breast cancer
by: E. A. Kim, et al.
Published: (2014-08-01) -
Various doses of statins and coronary angiogenesis in patients with coronary heart disease
by: I. V. Sergienko, et al.
Published: (2009-10-01) -
From bench to bedside: elucidating VEGF(R) inhibitor-related heart failure in cancer treatment
by: Shengkun Peng, et al.
Published: (2025-01-01)